SCHEMBL505299

SCHEMBL505299

O=C1Nc2c(cc(Cl)cc2[N+](=O)[O-])C1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 8/20 0.59
DNMT1 P26358 1/20 0.59
AKR1B1 P15121 1/20 0.43
TGM2 P21980 2/20 0.42
CASP3 P42574 2/20 0.41
CAPN9 O14815 1/20 0.41
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
GSK3B P49841 1/20 0.39
NSD2 O96028 1/20 0.39
BCHE P06276 1/20 0.39
DAO P14920 1/20 0.39
GAA P10253 1/20 0.39
KIF18A Q8NI77 1/20 0.38
MEN1 O00255 1/20 0.37
MITF O75030 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
CACNA1B Q00975 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9016208 0.81 CAPN9 (0.54) CES1DNMT1AKR1B1TGM2CASP3
SCHEMBL504966 0.80 TGM2 (0.59) CES1DNMT1TGM2CASP3CAPN9
SCHEMBL505202 0.80 S100A4 (0.49) CES1DNMT1AKR1B1TGM2CASP3
SCHEMBL505131 0.80 ALDH1A1 (0.56) CES1DNMT1TGM2CASP3CAPN9
SCHEMBL5482259 0.76 CES1 (0.47) CES1DNMT1TGM2CASP3CAPN9
SCHEMBL505285 0.76 ALDH1A1 (0.46) CES1CASP3CAPN9ALDH1A1MAPT
SCHEMBL8872843 0.75 CES1 (0.43) CES1DNMT1AKR1B1ALDH1A1TSHR
SCHEMBL7393532 0.75 ALDH1A1 (0.41) CES1DNMT1AKR1B1ALDH1A1MAPT
SCHEMBL7393535 0.75 ALDH1A1 (0.41) CES1DNMT1AKR1B1ALDH1A1MAPT
SCHEMBL8923330 0.75 CES1 (0.58) CES1DNMT1AKR1B1TGM2CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000038636-A1 AGENT FOR DYING KERATIN FIBERS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2000-07-06 WO claimed
CN-107922430-B 2-substituted benzimidazole-4-formamide compound and preparation method and application thereof 中国科学院上海药物研究所 2020-09-04 CN disclosed
US-9006454-B2 Dihydroorotate dehydrogenase inhibitors MERCK SERONO S.A. (CH) 2015-04-14 US disclosed
US-9006454-B2 Dihydroorotate dehydrogenase inhibitors MERCK SERONO S.A. (CH) 2015-04-14 US disclosed
US-9006454-B2 Dihydroorotate dehydrogenase inhibitors MERCK SERONO S.A. (CH) 2015-04-14 US disclosed
CN-104030987-A DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO SA 2014-09-10 CN disclosed
EP-2414328-A2 DIHYDROOROTATE DEHYDROGENASE INHIBITORS Merck Serono S.A. (CH) 2012-02-08 EP disclosed
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2012-02-02 US disclosed
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2012-02-02 US disclosed
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2012-02-02 US disclosed
WO-2010115736-A2 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2010-10-14 WO disclosed
WO-2010115736-A2 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2010-10-14 WO disclosed
WO-2000038636-A1 AGENT FOR DYING KERATIN FIBERS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2000-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS DHODH, FH, DPYD CES1 846/4885DNMT1 1090/4885AKR1B1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.